Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer

Siesing, Christina LU ; Sorbye, Halfdan ; Dragomir, Anca ; Pfeiffer, Per ; Qvortrup, Camilla ; Pontén, Fredrik ; Jirström, Karin LU orcid ; Glimelius, Bengt and Eberhard, Jakob LU (2017) In PLoS ONE 12(8).
Abstract

Background: High expression of the RNA-binding motif protein 3 (RBM3) has been shown to correlate, with prolonged survival in several malignant diseases and with the benefit of platinum-based chemotherapy in ovarian cancer. The aim of this study was to evaluate RBM3 in metastatic colorectal cancer (mCRC) as a prognostic factor for overall survival and in relation to benefit of first-line chemotherapy. Methods: Immunohistochemical staining was conducted and evaluated in tumours from 455 mCRC patients. Kaplan-Meier analysis and Cox regression proportional hazards models were used to access the impact of RBM3 expression on overall survival (OS) and progression-free survival (PFS). Results: High RBM3 expression, both nuclear and... (More)

Background: High expression of the RNA-binding motif protein 3 (RBM3) has been shown to correlate, with prolonged survival in several malignant diseases and with the benefit of platinum-based chemotherapy in ovarian cancer. The aim of this study was to evaluate RBM3 in metastatic colorectal cancer (mCRC) as a prognostic factor for overall survival and in relation to benefit of first-line chemotherapy. Methods: Immunohistochemical staining was conducted and evaluated in tumours from 455 mCRC patients. Kaplan-Meier analysis and Cox regression proportional hazards models were used to access the impact of RBM3 expression on overall survival (OS) and progression-free survival (PFS). Results: High RBM3 expression, both nuclear and cytoplasmic, was an independent prognostic factor for prolonged OS (hazard ratio [HR] 0.67, 95% confidence interval [CI] 0.50–0.90 and HR 0.66, 95% CI 0.48–0.91, respectively). PFS was significantly longer in patients with high RBM3 expression who had received first-line oxaliplatin based treatment, compared to those who had received irinotecan based treatment, both regarding nuclear and cytoplasmic expression (p-value 0.020 and 0.022 respectively). Conclusion: High RBM3 expression is an independent predictor of prolonged survival in mCRC patients, in particular in patients treated with first-line oxaliplatin based chemotherapy.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
PLoS ONE
volume
12
issue
8
article number
e0182512
publisher
Public Library of Science (PLoS)
external identifiers
  • scopus:85027283404
  • pmid:28800641
  • wos:000407431800019
ISSN
1932-6203
DOI
10.1371/journal.pone.0182512
language
English
LU publication?
yes
id
5270ff73-aa1a-42d5-a6b7-c3bcacbfe1f3
date added to LUP
2017-09-04 10:49:02
date last changed
2024-03-31 16:06:01
@article{5270ff73-aa1a-42d5-a6b7-c3bcacbfe1f3,
  abstract     = {{<p>Background: High expression of the RNA-binding motif protein 3 (RBM3) has been shown to correlate, with prolonged survival in several malignant diseases and with the benefit of platinum-based chemotherapy in ovarian cancer. The aim of this study was to evaluate RBM3 in metastatic colorectal cancer (mCRC) as a prognostic factor for overall survival and in relation to benefit of first-line chemotherapy. Methods: Immunohistochemical staining was conducted and evaluated in tumours from 455 mCRC patients. Kaplan-Meier analysis and Cox regression proportional hazards models were used to access the impact of RBM3 expression on overall survival (OS) and progression-free survival (PFS). Results: High RBM3 expression, both nuclear and cytoplasmic, was an independent prognostic factor for prolonged OS (hazard ratio [HR] 0.67, 95% confidence interval [CI] 0.50–0.90 and HR 0.66, 95% CI 0.48–0.91, respectively). PFS was significantly longer in patients with high RBM3 expression who had received first-line oxaliplatin based treatment, compared to those who had received irinotecan based treatment, both regarding nuclear and cytoplasmic expression (p-value 0.020 and 0.022 respectively). Conclusion: High RBM3 expression is an independent predictor of prolonged survival in mCRC patients, in particular in patients treated with first-line oxaliplatin based chemotherapy.</p>}},
  author       = {{Siesing, Christina and Sorbye, Halfdan and Dragomir, Anca and Pfeiffer, Per and Qvortrup, Camilla and Pontén, Fredrik and Jirström, Karin and Glimelius, Bengt and Eberhard, Jakob}},
  issn         = {{1932-6203}},
  language     = {{eng}},
  number       = {{8}},
  publisher    = {{Public Library of Science (PLoS)}},
  series       = {{PLoS ONE}},
  title        = {{High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer}},
  url          = {{http://dx.doi.org/10.1371/journal.pone.0182512}},
  doi          = {{10.1371/journal.pone.0182512}},
  volume       = {{12}},
  year         = {{2017}},
}